Impact of disease-modifying therapies on brain and spinal cord atrophy in multiple sclerosis

Journal of Neuroimaging

Volumn 14, Issue SUPPL. 3, 2004, Pages

  Rudick, Richard A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Brain atrophy; Clinical trials; Disease modifying agents; Glatiramer acetate; Interferon ; Multiple sclerosis; Spinal cord atrophy

Indexed keywords

ALEMTUZUMAB; BETA1A INTERFERON; CLADRIBINE; GADOLINIUM; GLATIRAMER; INTERFERON BETA SERINE; METHYLPREDNISOLONE; PLACEBO; RILUZOLE;

BRAIN ATROPHY; BRAIN TISSUE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DISABILITY; DISEASE COURSE; ENCEPHALITIS; HUMAN; MULTIPLE SCLEROSIS; RELAPSE; REVIEW; SPINAL CORD ATROPHY;

EID: 2942656835     PISSN: 10512284     EISSN: None     Source Type: Journal    
DOI: 10.1177/1051228404266269     Document Type: Review

References (49)

1. Compston A, Coles A. Multiple sclerosis. Lancet 2002;359:1221-1231.
2. Wiendl H, Kieseier BC. Disease-modifying therapies in multiple sclerosis: an update on recent and ongoing trials and future strategies. Expert Opin Investig Drugs 2003;12:689-712.
3. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661.
4. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995;45:1268-1276.
5. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294.
6. Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis (PRISMS) Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-1504.
7. Galetta SL, Markowitz C, Lee AG. Immunomodulatory agents for the treatment of relapsing multiple sclerosis: a systematic review. Arch Intern Med 2002;162:2161-2169.
8. Rudick RA, Fisher E, Lee J-C, Simon J, Jacobs L. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 1999;53:1698-1704.
9. Simon JH, Jacobs LD, Campion MK, et al. A longitudinal study of brain atrophy in relapsing multiple sclerosis. Neurology 1999;53:139-148.
10. Rudick RA, Fisher E, Lee J-C, Duda JT, Simon J. Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon β-1a. Mult Scler 2000;6:365-372.
11. Bakshi R, Benedict RHB, Bermel RA, Jacobs L. Regional brain atrophy is associated with physical disability in multiple sclerosis: semiquantitative MRI and relationship to clinical findings. J Neuroimaging 2001;11:129-136.
12. Pelletier J, Suchet L, Witjas T, et al. A longitudinal study of callosal atrophy and interhemispheric dysfunction in relapsing-remitting multiple sclerosis. Arch Neurol 2001;58:105-111.
13. Dalton CM, Brex PA, Jenkins R, et al. Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis. J Neurol Neurosurg Psychiatry 2002;73:141-147.
14. Fisher E, Rudick RA, Simon JH, et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology 2002;59:1412-1420.
15. Turner B, Lin X, Calmon G, Roberts N, Blumhardt LD. Cerebral atrophy and disability in relapsing-remitting and secondary progressive multiple sclerosis over four years. Mult Scler 2003;9:21-27.
16. Molyneux PD, Kappos L, Polman C, et al. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. Brain 2000;123:2256-2263.
17. European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998;352:1491-1497.
18. Losseff NA, Wang L, Lai HM, et al. Progressive cerebral atrophy in multiple sclerosis: a serial MRI study. Brain 1996;119:2009-2019.
19. Frank JA, Richert N, Bash C, et al. Interferon-β-1b slows progression of atrophy in RRMS: three-year follow-up in NAb- and NAb+ patients. Neurology 2004;62:719-725.
20. Leary SM, Miller DH, Stevenson VL, Brex PA, Chard DT, Thompson AJ. Interferon β-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology 2003;60:44-51.
21. Losseff NA, Webb SL, O'Riordan JI, et al. Spinal cord atrophy and disability in multiple sclerosis: a new reproducible and sensitive MRI method with potential to monitor disease progression. Brain 1996;119:701-708.
22. Fox NC, Freeborough PA. Brain atrophy progression measured from registered serial MRI: validation and application to Alzheimer's disease. J Magn Reson Imaging 1997;7:1069-1075.
23. Hardmeier M, Freitag P, Wagenpfeil S, et al. Short and long term brain volume changes after initiation of treatment with rIFN-beta-1A in multiple sclerosis (MS) [abstract]. J Neurol 2002;249(suppl 1):I/20.
24. Clanet M, Radue EW, Kappos L, et al. A randomized, double-blind, dose-comparison study of weekly interferon β-1a in relapsing MS. Neurology 2002;59:1507-1517.
25. Jones CK, Riddehough A, Li DKB, et al. MRI cerebral atrophy in relapsing-remitting MS: results from the PRISMS trial [abstract]. Neurology 2001;56(suppl 3):A379.
26. Comi I, Inglese M, De Stefano N, et al. Brain volume changes in patients at presentation with suspected multiple sclerosis: results from the ETOMS study [abstract]. Mult Scler 2002;8(suppl 1):S10.
27. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001;357:1576-1582.
28. Lin X, Tench CR, Turner B, Blumhardt LD, Constantinescu CS. Spinal cord atrophy and disability in multiple sclerosis over four years: application of a reproducible automated technique in monitoring disease progression in a cohort of the interferon β-1a (Rebif) treatment trial. J Neurol Neurosurg Psychiatry 2003;74:1090-1094.
29. The Prevention of Relapses and Disability by Interferon-β-1a Subcutaneously in Multiple Sclerosis (PRISMS) Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-β-1a in relapsing MS. Neurology 2001;56:1628-1636.
30. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 2001;56:1496-1504.
31. Gasperini C, Paolillo A, Giugni E, et al. MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a. Mult Scler 2002;8:119-123.
32. Paolillo A, Pozzilli C, Giugni E, et al. A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with interferon-beta. Eur J Neurol 2002;9:645-655.
33. Ge Y, Grossman RI, Udupa JK, et al. Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment. Neurology 2000;54:813-817.
34. Rovaris M, Comi G, Rocca MA, Wolinsky JS, Filippi M. Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications. European/Canadian Glatiramer Acetate Study Group. Brain 2001;124:1803-1812.
35. Comi G, Filippi M, Wolinsky JS, and the European/Canadian Glatiramer Acetate Study Group. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging: measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001;49:290-297.
36. Rovaris M, Inglese M, van Schijndel RA, et al. Sensitivity and reproducibility of volume change measurements of different brain portions on magnetic resonance imaging in patients with multiple sclerosis. J Neurol 2000;247:960-965.
37. Sormani MP, Rovaris M, Valsasina P, Wolinsky JS, Comi G, Filippi M. Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis. Neurology 2004;62:1432-1434.
38. Wolinsky JS, Narayana PA, Johnson KP. United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Copolymer 1 Multiple Sclerosis Study Group, MRI Analysis Center. Mult Scler 2001;7:33-41.
39. Johnson KP, Brooks BR, Ford CC, et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Mult Scler 2000;6:255-266.
40. Zivadinov R, Rudick RA, De Masi R, et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2001;57:1239-1247.
41. Kalkers NF, Barkhof F, Bergers E, van Schijndel R, Polman CH. The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study. Mult Scler 2002;8:532-533.
42. Paolillo A, Coles AJ, Molyneux PD, et al. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology 1999;53:751-757.
43. Rice GP, Filippi M, Comi G. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology 2000;54:1145-1155.
44. Filippi M, Rovaris M, Iannucci G, Mennea S, Sormani MP, Comi G. Whole brain volume changes in patients with progressive M S treated with cladribine. Neurology 2000;55:1714-1718.
45. Ge Y, Grossman RI, Udupa JK, et al. Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis. Radiology 2000;214:665-670.
46. Fisher E, Rudick RA, Cutter G, et al. Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients. Mult Scler 2000;6:373-377.
47. Kalkers NF, Bergers E, Castelijns JA, et al. Optimizing the association between disability and biological markers in MS. Neurology 2001;57:1253-1258.
48. Zivadinov R, Sepcic J, Nasuelli D, et al. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2001;70:773-780.
49. Bermel RA, Sharma J, Tjoa CW, Puli SR, Bakshi R. A semiautomated measure of whole-brain atrophy in multiple sclerosis. J Neurol Sci 2003:208;57-65